登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
ClinicalTrials.gov 上登记的一项胃癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06121700,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
TSH is within the normal range; if TSH is out of the normal range, FT3 and FT4 should be investigated. If the test results of FT3/FT4 cannot be obtained, T3 and T4 can be accepted. 13. If the level of T3/T4 is normal, the patients can be selected.
入选标准第 14 条
Female patients agree to take contraceptive measures during treatment and within 120 days after the last dose of anti-PD-1 mAb or 180 days after the last use of chemotherapy or radiotherapy.
入选标准第 21 条
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.
入选标准第 7 条
At least one evaluable lesion in CT/MRI according to RESIST 1.1 is required.
入选标准第 3 条
Known history of human immunodeficiency virus (HIV) infection.
排除标准第 29 条
Patients with untreated chronic hepatitis B or HBV-DNA exceeding 500 IU/ml or HCV-RNA positive.
排除标准第 30 条
Female patients should not be pregnant or breast feeding.
入选标准第 20 条
Pregnant or lactating females or females planning to become pregnant or lactating. Women of childbearing age with a positive pregnancy test or without a pregnancy test in the baseline period. Menopausal women must have stopped menstruating for at least 12 months before being considered to have no chance of pregnancy.
排除标准第 3 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06121700,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Histopathologically confirmed adenocarcinoma of stomach (G) or gastroesophageal junction (GEJ) (excluding Siewert type I). Limited metastatic status of disease. At least one evaluable lesion in CT/MRI according to RESIST 1.1 is required. The status of HER2 is clear. pMMR/MSS confirmed by immunohistochemistry or gene test. Male or female. Patient age ≥ 18 years and ≤ 75 years. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1. Physical state or organ function can tolerate the planned treatment of the study protocol, including systematic chemotherapy, immunotherapy with anti-PD-1 monoclonal antibody (mAb), primary lesion radiotherapy, metastatic lesion radiotherapy, and surgical resection of primary and/or metastatic lesions. No previous surgery or antitumor therapies, including chemotherapy, radiotherapy, or immunotherapy, were administered. Adequate hematological function: absolute neutrophil count (ANC) ≥ 1.5×109/L; platelet count ≥ 100×109/L; hemoglobin level ≥ 90 g/L. Adequate hepatic function: total bilirubin ≤ 1.5×upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 × ULN in the absence of liver metastases, or < 5 × ULN in case of liver metastases; ALP ≤ 2.5×ULN; ALB ≥ 30 g/L. Adequate renal function: serum creatinine ≤ 1.5×ULN; creatinine clearance rate ≥ 60 ml/min. Adequate coagulation function: INR/PT ≤ 1.5×ULN; APTT ≤ 1.5×ULN. TSH is within the normal range; if TSH is out of the normal range, FT3 and FT4 should be investigated. If the test results of FT3/FT4 cannot be obtained, T3 and T4 can be accepted. 13. If the level of T3/T4 is normal, the patients can be selected. Urine test: urine protein<2+; if the urine protein≥2+, the 24-hour urine protein quantification must be≤1g. There is no serious concomitant disease, and the patient's life expectancy is more than 6 months. Patients agree to sign written informed consent before recruitment. Patients are willing and able to follow the protocol during the study, including receiving treatment and scheduled follow-up and examination. Patients are willing to provide samples of blood and tissue. Female patients should not be pregnant or breast feeding. Female patients agree to take contraceptive measures during treatment and within 120 days after the last dose of anti-PD-1 mAb or 180 days after the last use of chemotherapy or radiotherapy. Retroperitoneal lymph node metastases (RPLM) only or at maximum one organ involved with or without RPLM. There is no peritoneal seeding on diagnostic laparoscopy (P0). The definition of RPLM includes but is not limited to para-aortal, intra-aorto-caval, parapancreatic or mesenteric lymph nodes. If the duodenum is invaded, retropancreatic nodes are not regarded as M1. The definition of single organ metastasis in the study is as follows: a) Liver: maximum of 5 metastatic lesions that are potentially resectable and the metastases should be limited to one lobe and not involve important blood vessels or bile ducts. b) Lung: unilateral involvement, potentially resectable. c) Ovary: uni- or bilateral Krukenberg tumors in the absence of macroscopic peritoneal carcinomatosis. d) Adrenal gland: uni- or bilateral metastases. e) Extra-abdominal lymph node metastases, such as supraclavicular or cervical lymph node involvement. f) Bone: localized bone involvement (defined as being within one radiation field). Other metastatic disease locations are considered, limited by the investigator and confirmed by the multidisciplinary team (MDT).排除标准:Exclusion Criteria:
Patients who have previously received surgery, chemotherapy, radiotherapy or immunotherapy for gastric cancer. Patients have a history of cancer in the five years before enrollment except for squamous or basal cell carcinoma of the skin that was effectively treated and superficial bladder cancer, cervical carcinoma in situ and breast cancer in situ that was treated by operation. Pregnant or lactating females or females planning to become pregnant or lactating. Women of childbearing age with a positive pregnancy test or without a pregnancy test in the baseline period. Menopausal women must have stopped menstruating for at least 12 months before being considered to have no chance of pregnancy. Patients who had sexual activity (with the possibility of childbirth) and were unwilling to use contraception during the study period. Patients with a history of allergies to any drugs that may be used in this study, including chemotherapy drugs. History of allogeneic stem cell transplantation or organ transplantation. Vaccinated with live vaccine within 28 days before recruitment. Immunotherapy (interleukin, interferon, thymine) or other experimental treatment was given 28 days before enrollment. History of anti-PD-1, PD-L1, PD-L2 or any other specific T-cell costimulation or checkpoint pathway targeted therapy. History of using steroids (dose > 10 mg/d prednisone) or other systemic immunosuppressive therapy within 14 days before recruitment, except for patients treated with the following regimen: steroids used for hormone replacement (dose > 10 mg/d prednisone); local application of steroids with little systemic absorption; short-term (≤ 7 days) use of steroids to prevent allergy or vomiting. Patients with weight loss of more than 20% within 2 months before recruitment. Uncontrolled systemic diseases, including diabetes, hypertension, etc. Uncontrollable pleural effusion, pericardial effusion, or ascites occurred within two weeks before recruitment. Failure of important organs (heart, lung, liver, kidney, etc.). Moderate or severe renal injury [creatinine clearance ≤ 50 ml/min (according to Cockcroft \& Gault equation)], or SCR > ULN. Dipyrimidine dehydrogenase (DPD) deficiency. Patients with central nervous system (CNS) disorders or tumors, including brain metastases, peripheral nervous system disorders or psychiatric diseases. Cerebrovascular accidents occurred within 6 months before recruitment. Patients with peripheral neuropathy of NCI-CTCAE grade 1, except for those with disappearance of the deep tendon reflex. Patients with a known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, congestive heart failure, cardiac infarction or cardiac insufficiency within 6 months prior to study recruitment. Pulmonary embolism occurred within 28 days before enrollment. Patients who had the following history of pulmonary diseases: interstitial lung disease, noninfectious pneumonia, pulmonary fibrosis, or acute lung disease. Patients with gastrointestinal bleeding or a high risk of bleeding within the first 2 weeks of enrollment. Patients who experienced gastrointestinal perforation or fistula within 6 months prior to enrollment. Upper gastrointestinal obstruction, dysfunction or malabsorption syndrome may affect the absorption of oral chemotherapy drugs. Patients who cannot swallow or take medication orally. Patients with a history of active autoimmune disease or refractory autoimmune disease. Severe chronic or active infections requiring systemic antibiotics, antifungal or antiviral therapy, including tuberculosis and AIDS. Known history of human immunodeficiency virus (HIV) infection. Patients with untreated chronic hepatitis B or HBV-DNA exceeding 500 IU/ml or HCV-RNA positive. Alcohol/drug abuse and medical, psychological or social conditions may interfere with patients' participation in the study or have an impact on the evaluation of the study results.
引自 ClinicalTrials.gov, NCT06121700, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06121700,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。